这页已由机器翻译。其他页面可能仍然显示为英文。 View in English

使用临床和血液生物标志物预测肺癌患者免疫治疗结果的诺米克图的开发和验证

Ting Ouyang ¹, Fei Zhang ², Yan Yang ³

¹Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China.
²Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
³Department of Medical Management, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
⁴Department of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China.
⁵Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000, China.
⁶Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
⁷Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000, China. chuxiaoyuan000@163.com.
⁸Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000, China. njjloncologycc@163.com.
⁹Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China. yangmi@nju.edu.cn.
¹⁰The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210000, China. yangmi@nju.edu.cn.

⁰Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China.

Bmc Cancer +

|

2025年八月22日

在PubMed上查看摘要

概括

这项研究使用临床和血液生物标志物来预测接受免疫检查点抑制剂 (ICI) 的肺癌患者的预后. 这些工具提供了准确的,具有成本效益的预测,以指导个性化治疗决策.

科学领域

癌症学
免疫疗法
生物标志物

背景情况

肺癌是全球癌症死亡的主要原因.
免疫检查点抑制剂 (ICI) 改善了结果,但有效性和副作用各不相同.
准确的预后工具对于优化ICI治疗决策至关重要.

研究的目的

开发和验证ICI治疗的肺癌患者的预后.
确定预测整体存活 (OS) 和无进展存活 (PFS) 的独立临床和血液生物标志物.

主要方法

用ICI治疗的436名肺癌患者的回顾性分析.
使用LASSO和考克斯回归来确定预后因素.
使用一致性指数,ROC曲线和决策曲线分析构建和验证名ograms.

主要成果

主要预测OS和PFS包括NLR,之前的手术,肝转移,临床阶段,治疗线和反应.
纳米图表显示出良好的预测准确性 (C指数为0. 655 - 0. 730).
通过诺姆图识别的高风险患者的生存期和PFS显著缩短.

结论

开发出结合临床和血液生物标志物的诺姆图谱提供了简单,准确和经济高效的预测工具.
对于接受ICI的肺癌患者来说,这些nomograms有助于个性化临床决策.
这项研究强调了生物标志物在预测ICI治疗结果中的有用性.

关键词:

免疫检查点抑制剂肺部癌症一个名字预测生物标志物

相关概念视频

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.